Breast surgery
Remove. Rebuild. Restore.
Advancing breast-conserving and reconstruction surgery with a combination of clinically-differentiated biologics, fluorescence and lighted visualization tools to help you see and do more.
With Stryker’s breast-focused products,
We See You. We’re here to support you.
Breast cancer is one of the most prevalent cancers worldwide, accounting for 1 in 8 cancer diagnoses1. Breast cancer treatment has many options. From diagnosis, to surgery or radiation and chemotherapy, breast cancer comes with many new experiences and unknowns.
.
SPY perfusion assessment
The SPY-PHI Fluorescence Imaging System also features SPY-QP. SPY-QP is an intraoperative and surgeon-controlled fluorescence assessment software designed to allow surgeons to objectively assess the intensity of the fluorescence signal through Relative Values (%) or a Color Maps mode3.
SPY lymphatic mapping
For visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with breast cancer, Stryker’s SPY-PHI System and SPY AGENT GREEN are currently the only fluorescence imaging system and fluorescence imaging agent on-label4.
SPY-PHI and SPY AGENT GREEN:
Successfully identified at least one histology-confirmed lymph node in 98% (145/148) of patients.5
Lymphatic vessel mapping aided visualization of 99% (357/360) of lymph nodes.5
.
.
Up to 22x more light output than
battery powered disposable retractors7
Comfort
Ergonomic, low-profile and ultra-lightweight design for use in deep cavities or through small incisions
Thermally cool
Thermally-cool illumination8 helps protect against thermal damage to tissues, surgical drapes, etc.
Protection
Proprietary polymer provides high strength and strong upward retraction and protects tissue from trauma and burns due to arcing from electrosurgical devices
.
LifeNet Health is our trusted partner with over 40 years of experience in tissue processing and holds the longest-running accreditation with the American Association of Tissue Banks (AATB).9
Optimal decellularization
MATRACELL® technology removes > 97% of donor DNA, allowing for rapid cellular infiltration and re-vascularization without sacrificing the graft’s biomechanical structure or biomechanical properties.10
Patient safety comes first
With a Sterility Assurance Level (SAL) of 10-6, DermACELL is as sterile as your implants and has a 1 in 1,000,000 chance of one viable microorganism on the graft.9
No rinse required
Preservon technology allows the graft to be stored at room temperature and is ready to use out of the packaging.9
A portfolio for everyone
DermACELL is available in standard, microperforated and shaped sizes across different thicknesses.
Want to learn more?
Join us at our National iSPIES event or Regional SPY Symposiums! Please contact bailey.harrington@stryker.com for more information.
iSPIES speaker and Principal Investigator of the FILM-B study, Dr. David Weintritt, on SPY in breast lymphatic mapping procedures for breast cancer treatment.
.
To locate a facility in the United States that uses SPY-PHI fluorescence imaging technology nearest you, please navigate to our patient website.
Contact us
Thank you for your submission
References
- Breast cancer statistics: How common is breast cancer?. Breast Cancer Statistics | How Common Is Breast Cancer? | American Cancer Society. (n.d.-b). https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
- 4-0003039 Rev. G - User Guide, SPY-PHI
- P46748 - User Guide, SPY-QP Fluorescence Assessment Software
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211580s006lbl.pdf
- Data from the Per-Protocol (PP) and Modified Intent-to-Treat (mITT) analysis populations (N=148)
- Stryker Engineering Data on File D0000083970
- Data on file: D0000015933 Rev. AA
- Stryker Engineering Data on File LIT 10668
- DermACELL, Instructions For Use
- TR-0269, PQ 10-083, LifeNet Health, Virginia Beach, VA.
Dermacell is intended for homologous use only. Homologous use refers to the allograft being used in a manner that that performs the same basic function in the recipient as in the donor. For Dermacell, this means the allograft must be minimally manipulated in the performance of a surgical procedure. Any use of Dermacell allograft(s) to perform pre-pectoral breast reconstruction or any use of Dermacell to extend the submuscular pocket for breast implant or tissue expander placement is considered an off-label use because it is a non-homologous use.
P/N: 1000904727